DHR: Bioprocessing Recovery Drives Path to Re-acceleration; Resume Coverage at Outperform

研报英文原文证据摘录

DHR: Bioprocessing Recovery Drives Path to Re-acceleration; Resume Coverage at Outperform

this strength has materialized even before any 2026 2.06A 1.83E 1.94E 2.60E

meaningful benefit from the >$500B in announced pharma reshoring All values in USD unless otherwise noted.

investment begins to flow through. Priced as of prior trading day's market close, EST (unless otherwise noted).

Base effects mask underlying momentum in diagnostics. Danaher is a

victim of its own success in respiratory testing. What was once a <$300M

sales item for its molecular diagnostics business has averaged $1.9B over

the past three years. Respiratory testing is inherently seasonal and variable;

the low-teens sales decline forecasted for 2026 (~100bps drag to total

Danaher growth) reflects year to year demand variability rather than any

structural demand deterioration.

The underlying diagnostics business continues to improve, absent

structural challenges in China. Danaher has been closing menu gaps in its

Beckman Coulter business (Hep B clearance in Q1 the latest), and as well

as its molecular diagnostics business. The Q1 FDA clearance of the Xpert GI

Panel marked Danaher's entry into the ~$2B multiplexed infectious disease

testing market, where we see strong right to win given its installed base of

>60,000 instruments.

Scope for further consistent capital deployment. We see continued

runway for Danaher to deploy capital inorganically in life sciences and

diagnostics. The upcoming Masimo acquisition in diagnostics should be

growth and margin accretive, and we see meaningful white space for

further consolidation in Life Sciences.

Valuation attractive at current relative trough. At ~0.9x, Danaher's relative

P/E vs the S&P 500 is at its lowest level over the past 5 years, a time where